1、White PaperSeizing the Moment:Biotechs Golden Opportunity for Self-CommercialisationLeapfrogging legacy models to realise the promise of lean,technology-centric commercialisationMARKUS GORES,Vice President,Thought Leadership,IQVIA THOMAS BAKER,Senior Vice President,Global Data,Technology,and Advisor

2、y Services,IQVIA CHARLES RINK,Senior Principal,Information Management&Analytics Technology,IQVIAMIKE SANVOISIN,Vice President,Biotech Commercial Services,IQVIATable of contentsExecutive summary 1Introduction 2A new era for commercialisation 3A golden opportunity for EBPs:Leapfrogging legacy models 6

3、Laying the foundation of the new model 7Modern data management:The core foundation of the technology-enabled EBP 8Envisioning the data-enabled EBP commercial engine 9The journey towards a technology-enabled commercial model 11Full-service affiliate outsourcing 13IQVIA capabilities:Supporting the EBP

4、 self-commercialisation journey 16About the authors 18 |1Health systems are increasingly led by digitally savvy decision makers who expect faster,more relevant,and personalised information.Alongside the rise of agentic AI and enabling technologies,this transformation in information requirements is u

5、pending traditional pharmaceutical go to market models by fundamentally rewriting the rules of commercialisation.For Emerging Biopharma Companies(EBPs)this creates a unique opportunity to maximise the value of their assets through self-commercialisation.Unencumbered by legacy commercial infrastructu

6、re,EBPs can leapfrog to a lean,technology-enabled commercial model,powered by purpose-built capabilities,that is fit for the future delivering speed,agility and precision engagement at scale.Unlike the traditional outsourcing model,a next-generation,technology-centric contract commercialisation part